Partnering

We are discovering and developing CRISPR-based therapies based on our patent-protected technology. We believe that precision editing of bacterial genomes has the potential to revolutionize the management of complex diseases directly impacted by the human microbiota, as well as difficult-to-treat condiations. Hence, we are pioneering a novel use of CRISPR to:

(a) selectively cut bacterial genes and kill target bacteria while leaving the rest of the patient’s microbial community intact

(b) introduce genes to resident commensal bacteria of the microbiota to enable in situ production of therapeutic proteins and peptides

Our novel therapeutic modality has enormous potential to modulate the human microbiome to transform the lives of patients in a range of therapeutic areas.

SNIPR Biome holds exclusive worldwide rights to foundational intellectual property covering CRISPR technology targeting bacteria for use in humans, including modulation of human microbiomes. Aspects of our patent portfolio relate to CRISPR compositions and methods of genome targeting in any bacteria for any indication and using any Cas nuclease or other guided nuclease.

Read about our granted patents

We are committed to exploiting the full potential of our technology by working with partners to discover and develop new therapies based on our novel CRISPR-based modality. We are seeking companies interested in leveraging the power of our transformational science through R&D partnerships and creating novel therapies together.

 
Talk to us: 
partnering@sniprbiome.com